cat no | io1081, io1082
ioGABAergic Neurons APP V717I/V717I are opti-ox deterministically programmed GABAergic neurons carrying a genetically engineered homozygous V7171 (London) mutation in the APP gene encoding the amyloid precursor protein. This mutation is linked to familial early-onset Alzheimer's disease (AD).
These cells offer a functional, rapidly maturing, and disease relevant system to study the role of the APP V717I (London) mutation in early-onset AD, alongside a genetically matched wild-type control.
Two clones are available, all genetically matched to the wild type control (ioGABAergic Neurons). The disease model cells and the wild-type control offer a physiologically relevant model to investigate the impact of the APP V717I mutation on cellular and molecular mechanisms and function in early-onset AD.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGABAergic Neurons to directly investigate the effect of the mutant APP protein on early-onset AD.
Highly pure
>99% of cells express key GABAergic markers within 4 days post-thaw, allowing consistent and reproducible results from every vial.
Co-culture compatible
Suitable for co-culture and tri-culture studies with ioGlutamatergic Neurons and astrocytes.
Disease model cells express key GABAergic neuron-specific markers comparably to the isogenic control
Disease model cells form structural neuronal networks by day 12
Disease model cells demonstrate gene expression of neuronal and GABAergic-specific markers following deterministic programming
Dr Brian Gill, MD | Assistant Professor of Neurological Surgery| Columbia University Irving Medical Center
Dr Tony Oosterveen | Principal Scientist and CNS Lead, Neurobiology | bit.bio
Whitehouse, et al
JoVE Journal of Visualized Experiments
2023
Using ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
V6
bit.bio
2023
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | bit.bio
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
bit.bio
Dr Deepak Srivastava | King’s College London
Dr Mariangela Iovino | Group Leader | Charles River
Dr Tony Oosterveen | Senior Scientist | bit.bio
Davenport A, Frolov T & Kotter M
Drug Discovery World
2020
In this webinar, Dr Rodney Bowling, CSO of Everlum Bio, offers an expert discussion on their use of ioGABAergic neurons for the screening of antisense oligonucleotide (ASO) based RNA therapeutics to accelerate the discovery of novel personalised therapies for rare autism spectrum disorders (ASD).